Multimodal therapy in locally advanced gastric cancer;Multimodale Therapie beim lokal fortgeschrittenen Magenkarzinom

Deutsche Medizinische Wochenschrift

Volumn 136, Issue 43, 2011, Pages 2205-2211

  Bolke E ^a   Peiper, M ^b   Knoefel, W T ^a   Baldus, S E ^a   Schauer, M ^a   Matuschek, C ^a   Gerber, P A ^a   Hoff, N P ^a   Budach, W ^a   Gattermann, N ^a   Erhardt, A ^a   Scherer, A ^a   Buhren, B A ^a   Orth, K ^c  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Eye Hospital   (Germany)

^c Klinikum Region Hannover   (Germany)

Author keywords

chemotherapy; gastric cancer; neoadjuvant; radio chemotherapy

Indexed keywords

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; HUMAN; MULTIMODALITY CANCER THERAPY; REVIEW; STOMACH CANCER;

CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; LYMPH NODE EXCISION; NEOADJUVANT THERAPY; NEOPLASM MICROMETASTASIS; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 80054869893     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0031-1292034     Document Type: Review

References (59)

1. Barbour A P., Rizk N P., Gerdes H et al,. Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction. J Am Coll Surg 2007 205 593-596
2. Barbour A P., Rizk N P., Gonen M et al,. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg 2007 246 1-8 (Pubitemid 47012198)
3. Becker K, Langer R, Reim D et al,. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 2011 253 934-939
4. Beer A J., Wieder H A., Lordick F et al,. Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. Radiology 2006 239 472-480
5. Boige V, Pignon J P., Saint-Aubert B et al,. Final results of a randomized trial comparing preoperative 5-fluorouracil (F) cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC Accord07-FFCD 9703 trial. J Clin Oncol 2007 25 4510
6. Brücher B L., Becker K, Lordick F et al,. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 2006 106 2119-2127 (Pubitemid 43673232)
7. Brücher B L., Swisher S G., Königsrainer A et al,. Response to preoperative therapy in upper gastrointestinal cancers. Ann Surg Oncol 2009 16 878-886
8. Buyse M, Pignon J. Meta-analysis of randomized trials assessing the interest of postoperative chemotherapy and prognostic factors in gastric cancer. J Clin Oncol 2009 25 211
9. Chang F, Deere H, Mahadeva U et al,. Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: practical guidelines and current issues. Am J Clin Pathol 2008 129 252-262 (Pubitemid 352029316)
10. Cunningham D, Allum W H., Stenning S P. et al,. MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006 355 11-20
11. Dikken J L., Jansen E P., Cats A et al,. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 2010 28 2430-2436
12. Earle C C., Maroun J A. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revistiting a meta-analysis of randomized trials. Eur J Cancer 1999 35 1059-1064 (Pubitemid 29339187)
13. Feussner H, Hartl F. Staging laparoscopy in oncology. Chirurg 2006 77 971-980 (Pubitemid 44875473)
14. Fiorica F, Di Bona D, Schepis F et al,. Preoperative chemoradiotherapy in oesophageal cancer: a systematic review and meta-analysis. Gut 2004 53 925-930 (Pubitemid 38824146)
15. Gebski V, Burmeister B, Smithers B M. et al,. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007 8 226-234 (Pubitemid 46291702)
16. Heidecke C D., Weinghardt H, Feith M et al,. Neoadjuvant treatment of esophageal cancer: Immunosuppression following combined radiochemotherapy. Surgery 2002 132 495-501 (Pubitemid 35155484)
17. Janunger K G., Hafström L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg Oncol 2002 168 597-608 (Pubitemid 36355892)
18. Jensen A D., Grehn C, Nikoghosyan A et al,. Catch me if you can the use of image guidance in the radiotherapy of an unusual case of esophageal cancer. Strahlenther Onkol 2009 185 469-473
19. Jouve J, Michel P, Mariette C et al,. Federation Francophone de Cancerologie Digestive. Outcome of the nonrandomized patients in the FFCD 9102 trial: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus. J Clin Oncol 2008 26 4555
20. Kim S, Lim D H., Lee J et al,. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radia Oncol Biol Phys 2005 63 1279-1285 (Pubitemid 41628018)
21. Leibl B J., Vitz S, Schäfer W et al,. Adenocarcinoma of the esophagogastric junction: neoadjuvant radiochemotherapy and radical surgery: early results and toxicity. Strahlenther Onkol 2011 187 231-237
22. Lordick F, Ott K, Krause B J. et al,. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007 8 797-805 (Pubitemid 47308659)
23. Lordick F, Ruers T, Aust D E. et al,. European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer 2008 44 1807-1819
24. Lordick F, Stein H J., Peschel C et al,. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 2004 91 540-551 (Pubitemid 38624660)
25. Lowy A M., Mansfield P F., Leach S D. et al,. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999 229 303-308 (Pubitemid 30191763)
26. Macdonald J S., Smalley S R., Benedetti J et al,. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001 345 725-730
27. Mari E, Floriani I, Tinazzi A et al,. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of puplished randomized trials. A study of the GISCAD. Ann Oncol 2000 11 837-843
28. Mizumoto M, Sugahara S, Nakayama H et al,. Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer. Strahlenther Onkol 2010 186 482-488
29. Napieralski R, Ott K, Kremer M et al,. Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: Relation to therapy response and clinicopathologic and molecular features. Clin Cancer Res 2007 13 5095-5102 (Pubitemid 47502076)
30. Ott K, Fink U, Becker K et al,. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003 21 4604-4610 (Pubitemid 46594034)
31. Ott K, Herrmann K, Lordick F et al,. Early metabolic response evaluation by fluorine-18 fluorodesoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long term results of a prospective study. Clin Cancer Res 2008 14 2012-2018 (Pubitemid 351551110)
32. Ott K, Vogelsang H, Marton N et al,. The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer. Int J Cancer 2006 119 2885-2894 (Pubitemid 44846241)
33. Ott K, Vogelsang H, Mueller J et al,. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 2003 9 2307-2315 (Pubitemid 36687657)
34. Ott K, Weber W A., Lordick F et al,. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006 24 4692-4698 (Pubitemid 46646244)
35. Saka M, Mudan S S., Katai H et al,. Pancreaticoduodenectomy for advanced gastric cancer. Gastric Cancer 2005 8 1-5 (Pubitemid 40394917)
36. Sakuramoto S, Sasako M, Yamaguchi T et al,. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007 357 1810-1820 (Pubitemid 350044801)
37. Sasako M, Sano T, Yamamoto S et al,. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008 359 453-462
38. Sasako M, Sano T, Yamamoto S et al,. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006 7 644-651 (Pubitemid 44123569)
39. Schneider P M., Baldus S E., Metzger R et al,. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 2005 242 684-692 (Pubitemid 41567124)
40. Schuhmacher C, Böttcher K, Siewert J R. Intestinal pouches: gastric reconstruction. Chirurg 1999 70 520-529
41. Schuhmacher C P., Fink U, Becker K et al,. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin and cisplatin. Closing results after 5 years of follow-up. Cancer 2001 91 918-927
42. Schumacher C, Schlag P, Lordick F et al,. Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia; Ranomized EORTC phase III trial. J Clin Oncol 2006 27 4510
43. Schuhmacher C, Gretschel S, Lordick F et al,. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010 28 5210-5218
44. Schwartz G K., Winter K, Minsky B D. et al,. Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regiments as adjuvant therapy in resected gastric cancer (RTOG-0114). J Clin Oncol 2009 27 1956-1962
45. Songun I, Putter H, Kranenbarg E M. et al,. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010 11 439-449
46. Stahl M, Walz M K., Stuschke M et al,. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009 27 851-856
47. Stahl M, Wilke H, Stuschke M et al,. Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol 2005 131 67-72
48. Stein H J., Feith M, Siewert J R. Neoadjuvante Therapie im oberen Gastrointestinaltrakt, Aktuelle Konzepte beim Barrett-Karzinom. Chirurg 2009 80 1019-1022
49. Tepper J E., Krasna M, Niedzwiecki D et al,. Superiority of trimodality therapy to surgery alone in esophageal cancer: Results of CALGB 9781. J Clin Oncol 2006 24 4012
50. Urba S G., Orringer M B., Turrisi A et al,. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001 19 305-313 (Pubitemid 32112841)
51. Van Cutsem E, Kang Y, Chung H et al,. Efficacy results of the Toga trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009 27 204
52. van der Gaast A V., van Hagen P, Hulshof M et al,. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized pase III study ASCO meeting 2010.
53. Walsh T N., Noonan N, Hollywood D et al,. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996 335 462-467 (Pubitemid 26269945)
54. Weber W A., Ott K, Becker K et al,. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001 19 3058-3065 (Pubitemid 32565444)
55. Wieder H A., Beer A J., Lordick F et al,. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 2005 46 2029-2034 (Pubitemid 46657450)
56. Wilke H, Preusser P, Fink U et al,. New developments in the treatment of gastric carcinoma. Cancer Treat Res 1991 55 363-373
57. Wolf M, Zehentmayr F, Niyazi M et al,. Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. Strahlenther Onkol 2010 186 374-381
58. Wu C W., Hsiung C A., Lo S S. et al,. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006 7 309-315
59. Zhang Z X., Gu X Z., Yin W B. et al,. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC) report on 370 patients. Int J Radiat Oncol Biol Phys 1998 42 929-934